Pexelizumab and Infarct Size in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. A Delayed Enhancement Cardiac Magnetic Resonance Substudy From the APEX-AMI Trial

JACC: Cardiovascular Imaging

Volumn 3, Issue 1, 2010, Pages 52-60

  Patel, Manesh R ^a   Worthley, Stephen G ^b   Stebbins, Amanda ^a   Dill, Thorsten ^c   Rademakers, Frank E ^d   Velleti, Uma S ^e   Barsness, Gregory W ^e   Van de Werf, Frans ^d   Hamm, Christian W ^c   Armstrong, Paul W ^f   Granger, Christopher B ^a   Kim, Raymond J ^a  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c KERCKHOFF HEART CENTER   (Germany)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

APEX AMI trial; cardiac magnetic resonance imaging; infarct size; pexelizumab

Indexed keywords

CREATINE KINASE; PEXELIZUMAB; PLACEBO;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG ELUTING STENT; FEMALE; HEART FAILURE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; SHOCK; ST SEGMENT ELEVATION; SYMPTOM; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; AUSTRALIA; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY CIRCULATION; EUROPE; FEMALE; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NORTH AMERICA; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SINGLE-CHAIN ANTIBODIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 73649092447     PISSN: 1936878X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcmg.2009.09.014     Document Type: Article

References (16)

1. Kloner R.A. Does reperfusion injury exist in humans?. J Am Coll Cardiol 21 (1993) 537-545
2. Amsterdam E.A., Stahl G.L., Pan H.L., Rendig S.V., Fletcher M.P., and Longhurst J.C. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol 268 (1995) H448-H457
3. Vakeva A.P., Agah A., Rollins S.A., Matis L.A., Li L., and Stahl G.L. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97 (1998) 2259-2267
4. Granger C.B., Mahaffey K.W., Weaver W.D., et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108 (2003) 1184-1190
5. Wagner A., Mahrholdt H., Holly T.A., et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 361 (2003) 374-379
6. Wu E., Judd R.M., Vargas J.D., Klocke F.J., Bonow R.O., and Kim R.J. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357 (2001) 21-28
7. Kim R.J., Albert T.S.E., Wible J.H., et al. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 117 (2008) 629-637
8. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100 (1999) 1992-2002
9. Fieno D.S., Kim R.J., Chen E.L., Lomasney J.W., Klocke F.J., and Judd R.M. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 36 (2000) 1985-1991
10. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 (2000) 1445-1453
11. Armstrong P.W., Adams P.X., Al-Khalidi H.R., et al. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 149 (2005) 402-407
12. Armstrong P.W., Granger C.B., et al., APEX Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 297 (2007) 43-51
13. Simonetti O.P., Kim R.J., Fieno D.S., et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218 (2001) 215-223
14. Wagner A., Mahrholdt H., Thomson L., et al. Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol 47 (2006) 2027-2033
15. Stone G.W., Dixon S.R., Grines C.L., et al. Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. Am J Cardiol 100 (2007) 1370-1375
16. Wu E., Ortiz J.T., Tejedor P., et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 94 (2008) 730-736